{"entity":{"id":"arpa-h","kind":"institution","name":"Advanced Research Projects Agency for Health","aka":["ARPA-H"],"tldr":"The US agency modelled on DARPA that funds high-risk, milestone-driven health programmes, including adaptive cancer therapy, rapid tumour-removal surgery and early detection.","summary":"Created in 2022 within the Department of Health and Human Services, ARPA-H funds programme managers to run time-limited, milestone-based projects that the NIH grant system does not, with an appropriation of roughly $1.5 billion per year in its first years. Cancer-relevant programmes include ADAPT (adaptive therapies that anticipate tumour evolution), POSEIDON (at-home multi-cancer screening), CUREIT (curative immunotherapy), Precision Surgical Interventions (removing all tumour tissue in one operation) and the Cancer Moonshot-aligned biomanufacturing efforts. It works through ARPANET-H hubs in Massachusetts, Texas and Washington and contracts rather than grants. Its model has drawn interest from other countries designing their own ARPA-style funders.","asOf":"2026-09-09","links":[{"label":"ARPA-H","url":"https://arpa-h.gov"},{"label":"Programs","url":"https://arpa-h.gov/research-and-funding/programs"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection","surgery","immunotherapy"],"technologies":["mced","fluorescence-guided-surgery","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":["alicia-jackson"],"bottlenecks":["b-resistance","b-early-detection","b-funding-allocation","b-surgery-radiation-innovation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Washington, DC","country":"US","lat":38.907,"lng":-77.037,"institutionType":"government","website":"https://arpa-h.gov","programs":["ADAPT (adaptive cancer therapy)","POSEIDON (at-home multi-cancer screening)","CUREIT and Precision Surgical Interventions","ARPANET-H hub network"]},"route":"/institutions/arpa-h/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"fluorescence-guided-surgery","kind":"technology","name":"Fluorescence-guided surgery","route":"/technologies/fluorescence-guided-surgery/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"person":[{"id":"alicia-jackson","kind":"person","name":"Alicia Jackson","route":"/people/alicia-jackson/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}]}}